PACS's 2026 Q2 Earnings Call: M&A Pipeline Mixed Bag vs. Underperforming Assets, Growth Strategy Split

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $1.43 billion, an increase of 9.1% year over year
• EPS: Adjusted EPS of $0.63, up 34% from $0.47 in the prior year
• Operating Margin: Adjusted EBITDA margin expanded 150 basis points year-over-year to 11.7%

Guidance:

• Full-year revenue guidance increased to $5.75B-$5.85B, representing 10% growth over 2025 at the midpoint.
• Full-year adjusted EBITDA guidance increased to $640M-$660M, representing 29% growth over 2025 at the midpoint.
• Guidance includes modest contribution from 20 Texas facilities acquired on August 1, but excludes remaining Aduro facilities and other pending acquisitions.
• Company expects to close additional facilities before year-end.

Business Commentary:

Revenue and EBITDA Growth:

• PACS Group reported revenue of $1.43 billion for Q2 2026, an increase of 9.1% year-over-year. Adjusted EBITDA grew by 25% compared to the prior year.
• The growth was driven by the sustainability of their operating model, improvements in quality outcomes, increased occupancy, and a stronger patient mix.

Same-Store Performance:

• The company's same-store skilled nursing revenue increased by 5.8% to $1.35 billion, with a same-store occupancy increase of 150 basis points.
• This performance reflects the strength of their existing portfolio, with improvements in occupancy and skilled mix driven by effective leadership and operational execution.

Skilled Nursing Facility Progression:

• PACS Group's skilled nursing portfolio includes 184 mature facilities, 100 ramping facilities, and 6 new facilities, reflecting significant progress in integrating acquired facilities.
• The progression through these cohorts contributes to organic growth, with new and ramping facilities expected to continue improving towards mature operating levels.

Acquisition Activity:

• PACS Group acquired 34 skilled nursing facilities from Aduro Healthcare, adding 3,633 skilled nursing beds across multiple states.
• The acquisition strategy focuses on expanding in existing markets and leveraging the PACS operating model to enhance clinical and financial performance.

Quality and Regulatory Compliance:

• 239 out of 284 skilled nursing facilities were rated four or five stars, with mature facilities achieving an average rating of 4.5.
• The focus on quality outcomes and regulatory compliance has strengthened trust with hospitals and payers, supporting admissions and occupancy levels.

Sentiment Analysis:

Overall Tone: Positive

• "We're pleased to report another strong quarter for PACS and to close out the first half of 2026 with continued momentum." "We're very pleased with our second quarter performance and the strong momentum we've maintained." "Our updated guidance reflects confidence in the underlying performance of our existing portfolio."

Q&A:

• Question from Benjamin Rossi (JP Morgan): Can you walk us through what you're seeing with your business and how trends year-to-date have given you this added confidence in your earnings growth during the back half of the year?
  Response: The guidance raise reflects continued strength across all cohorts in the first half, including occupancy, skilled mix, quality, and cash flow, with integration activity from the Aduro transaction accounted for.

• Question from Benjamin Rossi (JP Morgan): Can you walk through what's changed operationally across the ramping cohort and what's expected for the remainder of the year?
  Response: Ramping facilities show improved occupancy and skilled mix due to strong leadership and community reputation leading to more managed care agreements and stabilized labor costs, with substantial upside expected as they mature.

• Question from David McDonald (Truist Securities): How critical are your quality metrics in working with payers and securing referral sources?
  Response: Quality is fundamental; it allows the company to be competitive in negotiating managed care contracts and meet payer quality thresholds, providing a seat at the table for negotiations.

• Question from David McDonald (Truist Securities): How are you thinking about AI and automation for efficiency and clinical care?
  Response: AI tools are being explored and integrated to enhance efficiency, such as identifying patient care needs from medical records, improving documentation, and freeing up clinicians for direct care, with compliance being a key focus.

• Question from David McDonald (Truist Securities): Can you provide more detail on the acquisition pipeline?
  Response: The pipeline is active and diverse, with a mixed bag of opportunities from smaller regional operators to larger chunky deals, providing discipline and strategic optionality for growth.

• Question from AJ Rice (UBS): What are you seeing on Medicaid and managed care rate updates and contracting?
  Response: Medicaid rates have increased, with growth expected to continue due to quality-based incentives; Medicare and managed care rates are also increasing, with managed care payers focusing on quality and bed density.

• Question from AJ Rice (UBS): What are the dynamics around labor and any initiatives underway?
  Response: Labor market dynamics are improving, with lower contract labor as a percentage of revenue and no major issues with job postings, leading to margin expansion.

• Question from Raj Kumar (Stevens): Can you provide color on the revenue and earnings contribution from the 20 Texas facilities and how they compare to existing Texas facilities?
  Response: Guidance includes a modest contribution from the 20 Texas facilities, with revenue contributing more than EBITDA initially, but significant upside expected as they progress through the cohorts.

• Question from Raj Kumar (Stevens): Any sizing color on the Ohio supplemental quality incentive payments?
  Response: Payments have not been accrued as amounts are uncertain and timing is unknown, with receipt expected in the second half of the year, representing potential upside not included in guidance.

• Question from Ben Hendricks (RBC Capital Markets): What integration costs are expected for new facilities, particularly regarding agency utilization and administrative costs?
  Response: No significant step-up in agency labor is expected; integration will involve assessing existing teams, deploying systems, and strategic growth, with operational metrics expected to follow historical cohort progression.

Contradiction Point 1

Inclusion of Quality Incentive Payments in Financial Guidance

Contradiction on whether these payments are included in official guidance.

Raj Kumar (Stevens) asks about the company's Q4 earnings results? - Raj Kumar (Stevens)

2026Q2: The payments have not been received yet... They are not accrued for or included in guidance, representing potential upside. - [Carrie Hendrickson](CFO)

What are the specifics regarding Ohio's finalized quality incentive payments and whether they are included in the guidance? - Benjamin Rossi (JPMorgan)

2026Q1: Quality incentive payments (like WQIP in California and Ohio) are not included in guidance due to unpredictable timing and amounts. - [Carey Hendrickson](CFO)

Contradiction Point 2

Characterization of Labor Market Dynamics

Contradiction in describing the tone and state of the labor market.

Can you provide an update on the company's financial performance and future guidance? - David McDonald (Truist Securities)

2026Q2: Labor market dynamics are improving. Job postings are getting responses. - [Josh Jurgensen](COO)

How are labor dynamics, wage updates, and related initiatives impacting the company's operations and financial performance? - Raj Kumar (Stephens)

2026Q1: Labor trends are incredibly positive. There is strong interest in post-acute careers... - [Josh Jurgensen](COO)

Contradiction Point 3

M&A Pipeline Characterization and Growth Strategy Focus

Contradiction on whether pipeline is robust/mixed or consists mainly of underperforming assets.

David McDonald (Truist Securities) - David McDonald (Truist Securities)

2026Q2: M&A activity is high. The pipeline is a mixed bag, including smaller one-off deals, regional operators, and large, significant deals. - [Jason Murray](CEO)

Is the current pipeline larger than historical, and are there any significant "chunky" assets? - David MacDonald (Truist Securities)

20260227-2025 Q4: The 2026 guidance includes the acquisition of about 5 facilities per quarter, typically underperforming assets with low occupancy (60-70%) and minimal initial revenue. - [Mark Hancock](CFO)

Contradiction Point 4

Growth Strategy Emphasis on Acquisitions vs. De Novo Facilities

Contradiction on the primary growth driver being acquisitions or including significant de novo opportunities.

David McDonald (Truist Securities) - David McDonald (Truist Securities)

2026Q2: The pipeline is a mixed bag... This diversity provides optionality for disciplined and strategic growth. - [Jason Murray](CEO)

How does the current pipeline compare to historical in size, and are there any significant assets? - David MacDonald (Truist Securities)

20260227-2025 Q4: Historically, acquisitions have been the primary growth driver due to more attractive risk-adjusted returns and faster integration. - [Joshua Jergensen](COO)

Contradiction Point 5

New Facility Margin Progression

Contradiction on the expected margin trajectory for new facilities as they mature.

Benjamin Rossi (JP Morgan) - Benjamin Rossi (JP Morgan)

2026Q2: The ramping cohort... leads to increased executed managed care agreements and stabilization in labor costs... expanding revenue and margins. - [Josh Jurgensen](COO)

What operational changes have occurred across the ramping cohort, including facility mix, clinical programs, staffing, and referrals/rate design, and what are the expectations for the remainder of the year? - Benjamin Rossi (JPMorgan)

20251120-2025 Q3: New facilities typically start with a 2-3% margin, which improves as they progress. Ramping facilities see margins between 6-8%, and mature facilities reach low double-digits to low teens. - [Joshua Jergensen](COO)

<<>>